(IN BRIEF) University of Liverpool has announced that two of its researchers, Dr Hayley Lavender and Dr Paraskevi Kritsiligkou, have received Springboard Awards from the Academy of Medical Sciences, providing up to £125,000 in funding along with mentoring and career … Read the full press release
Posted in Awards, Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged Academy of Medical Sciences, antibiotic resistance, antifungal resistance, biomedical science, Claire Eyers, fungal infections, global health, Gonorrhoea, Hayley Lavender, immune system research, infectious disease research, microbial pathogenesis, Neisseria gonorrhoeae, Paraskevi Kritsiligkou, Springboard Awards, University of Liverpool, University of Liverpool Scientists Gain Major Funding to Tackle Global Health Threats from Drug Resistant Infections, University of Liverpool Strengthens Early Career Research with Academy of Medical Sciences Springboard Awards
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), achieved significant sales in Europe, triggering a USD 25 million milestone payment from partner Pfizer. This achievement highlights Cresemba’s strong performance in treating severe fungal infections. The milestone … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged Basilea Pharmaceutica, Cresemba®, David Veitch, Financial, fungal infections, investment
Ad hoc announcement pursuant to Art. 53 LR (PRESS RELEASE) BASEL/ ALLSCHWIL, 7-Sep-2022 — /EuropaWire/ — Basilea Pharmaceutica Ltd (SWX: BSLN), a commercial stage biopharmaceutical company, has announced the company has secured non-dilutive refinancing in the amount of CHF 75 … Read the full press release
Basel, Switzerland, 11-12-2013 — /EuropaWire/ — Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. QIDP status provides priority review and … Read the full press release
Posted in Government, Healthcare, Pharma & Biotech, Switzerland
Tagged Barbara Zink, Basilea Pharmaceutica, fungal infections, invasive aspergillosis, Isavuconazole, isavuconazonium sulfate, Peer Nils Schröder, QIDP, Qualified Infectious Disease Product, Ronald Scott, treatment, U.S. FDA, zygomycosis
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?